Targeting protein homeostasis holds potential to treat solid tumors and blood cancersDecember 03, 2015
Burlingame, Calif. - The success of proteasome inhibitors such as VELCADE® (bortezomib) and Kyprolis® (carfilzomib) for the treatment of multiple myeloma has shown that protein homeostasis, which is how cells maintain a balance of protein synthesis and degradation, is a valid pathway for developing drugs to treat cancer. However, attacking the proteasome in solid tumors has not worked to date. New research published in the journals Cancer Cell and the Journal of Medicinal Chemistry highlights a novel approach to target protein homeostasis by inhibiting the protein p97 in both solid tumors and blood cancers. Preclinical data to be presented at the 57th ASH Annual Meeting & Exposition show specifically that targeting p97 induces disease regression in the blood cancer acute myeloid leukemia (AML).
Cancer cells often produce an overabundance of proteins, particularly misfolded proteins that are toxic to cells. Therefore, cancer cells rely upon the ubiquitin proteasome system (UPS), which is responsible in both healthy and tumor cells for eliminating surplus, misfolded and mutant proteins. The hyper-active UPS in tumor cells is critical for their survival. Without it, toxic proteins accumulate, and the tumor cells die.
p97 is a key mediator of several protein homeostasis processes. Among them, p97 mediates the extraction of cellular proteins destined for destruction by the UPS from organelles, chromatin and protein complexes. Scientists from Cleave Biosciences published in the Journal of Medicinal Chemistry the discovery and optimization of an orally bioavailable small molecule called CB-5083 that inhibits p97. In the paper published in Cancer Cell, the same researchers demonstrated that CB-5083 had antitumor activity in cancer cell lines and in various mouse tumor models, indicating its potential as a drug candidate.
"Researchers over the years have identified multiple inhibitors of p97, but until now those compounds have not successfully inhibited tumor growth in vivo," said Mark Rolfe, Ph.D., senior author on the paper and President and Chief Scientific Officer at Cleave Biosciences. "If we can successfully translate this to treat both solid tumors and blood cancers, we could have a very powerful strategy for treating patients with these life-threatening diseases."
CB-5083 has the potential to provide a completely new way to combat solid tumors such as colon, lung or breast cancer, as well as a number of different blood cancers. Despite the success of the proteasome inhibitors in treating multiple myeloma, the majority of other blood cancers are not responsive to such agents. AML, the most common acute leukemia in adults, is an aggressive disease with very poor outcomes -- only a quarter of patients survive five years. However, the treatment paradigm has remained relatively unchanged for over 40 years. Targeting protein homeostasis with CB-5083 has the potential to achieve clinical benefit in patients with AML that historically have had few options.
In data generated from a collaboration between scientists at Cleave Biosciences, the University of Southern California, the University of Texas, San Antonio, and the Cleveland Clinic that will be presented at ASH, CB-5083 demonstrated its potential in both established AML cell lines as well as primary AML cells. Treatment with CB-5083 in seven unique AML cell lines and 10 specimens of AML cells derived directly from patients demonstrated reduced cell line survival and increased cell death. In addition, CB-5083 was highly active in three different AML cell lines that are resistant to conventional AML treatments. In vivo, treatment with CB-5083 in two different mouse models was well tolerated and induced disease regression.
"It is important to note that in AML, both established cell lines as well as cells that came directly from patients, also known as primary cells, showed similar sensitivity to CB-5083," noted Dr. Rolfe. "Typically, primary cells show reduced sensitivity to both conventional and experimental drugs in AML, indicating that CB-5083 could be a powerful tool against AML, especially in patients who have relapsed or refractory disease."
About Cleave Biosciences
Biopharmaceutical company Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems and have the potential to transform the treatment of people with difficult to treat solid tumors and hematologic malignancies. The company is privately held and located in Burlingame, California. For additional information, visit http://www.cleavebio.com.
Zhou, HJ, et al. 'Discovery of a First-in-Class, Potent, Selective and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)'. J. Med. Chem. DOI/10.1021/acs.jmedchem.5b01346
Anderson, DJ, et al. 'Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis'. Cancer Cell. DOI 10.1016/j.ccell.2015.10.002.
Nawrocki ST, et al. 'Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML' ASH Annual Meeting (2015) Session: 616, Abstract 1350
Related Multiple Myeloma Articles:
In an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy -- chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA.
Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators at the Medical University of South Carolina (MUSC) and elsewhere in an article published online on Dec.
In a study published in the scientific journal Oncotarget, researchers from Uppsala University show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease.
Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone.
Early intervention with an immunotherapy-based drug combination may prevent progression of high-risk 'smoldering' multiple myeloma to the full-blown disease, according to researchers from Dana-Farber Cancer Institute.
Researchers from UH Seidman Cancer Center and Case Western Reserve University School of Medicine presented new findings in multiple myeloma, lymphoma and other hematologic disorders at Annual Meeting of American Society of Hematology.
Carrying extra weight increases a person's risk that a benign blood disorder will develop into multiple myeloma, a blood cancer.
Scientists are moving closer to understanding how multiple myeloma takes hold in bone marrow by identifying what they believe are the mechanisms used by cancer cells to take over.
The only study presented was unsuitable for the benefit assessment.
In a new study, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma.
Related Multiple Myeloma Reading:
Multiple Myeloma: Diagnosis and Treatment
by Morie A. Gertz (Editor), S. Vincent Rajkumar (Editor)
This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses... View Details
The Myeloma Survival Guide: Essential Advice for Patients and Their Loved Ones, Second Edition (Volume 2)
by Jim Tamkin MD FACP FACE (Author), Dave Visel (Author)
The Myeloma Survival Guide makes sense of the difficult questions myeloma patients face, dealing with every aspect of life after diagnosis, from creating a wellness team to navigating treatment options to building a financial safety net. Jim Tamkin, Md, who lived with myeloma for 11 years, and Dave Visel share the insights they've gained as a doctor, patient, and caregiver, including:
Multiple Myeloma Patient Handbook: 2017 Edition
by International Myeloma Foundation
One of the most daunting aspects of being diagnosed with myeloma is learning about an unfamiliar disease that is quite complicated. The IMF’s Patient Handbook provides an overview of myeloma, with a focus on getting the correct diagnosis, the tests you really need, initial treatment options, and supportive care and how to get it. View Details
Multiple Myeloma: A Textbook for Nurses (Second Edition)
by Joseph Tariman (Author), Beth Faiman (Author)
The science of multiple myeloma is changing rapidly and this second edition provides nurses with the knowledge they need to stay informed and provide optimal care to a complex population of patients. The second edition of Multiple Myeloma: A Textbook for Nurses presents cutting-edge information on the treatment of multiple myeloma. New chapters discuss developments in genomics and biomarkers and promising clinical drug trials, covering major breakthroughs in clinical practice. View Details
Multiple Myeloma: The Plain English Handbook for Patients and Care Givers
by Robert J. Heller (Author)
A comprehensive handbook and guide in easy to understand terms dealing with Multiple Myeloma; the disease, treatments, medications, lifestyle changes, and resources. Written by a non-medical author and based upon personal experiences. Updated annually. View Details
The Ultimate Marathon: My Journey With Multiple Myeloma Cancer
by Tim McNeill (Author)
Tim McNeill was diagnosed with stage four Multiple Myeloma in June of 2002. Mr. McNeill’s original prognosis gave him only months if not weeks to live. As treatments began his kidneys failed and within days he contracted an MRSA infection. During the early days it was also discovered that the advanced stage of the cancer had destroyed several of the vertebrae in his back. This is the story of his early years of recovery. It is a story of personal perseverance and unrelenting determination. It is also the story of a family support group whose sheer will helped defy the medical odds for Mr.... View Details
100 Questions & Answers About Myeloma (100 Questions and Answers)
by Asad Bashey (Author), Rafat Abonour (Author), James W. Huston (Author)
Whether you're a newly diagnosed myeloma patient, a survivor, or a friend or relative of either, this book offers help. The only text to provide the doctor's and patient's views, 100 Questions & Answers About Myeloma, Third Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a hematologist-oncologist specializing in myeloma treatment, and featuring "insider" advice from an actual patient, this book is an invaluable resource for anyone coping with the... View Details
HOPE: Journey with Multiple Myeloma
by George Gadren Jr (Author)
Many people desire to write a book. I guess that piece for us is an attempt to make one immortal. Like so many other books, excluding the great ones, my attempt will end up on a dusty shelf with the pages untouched and that is just fine in my book, no pun intended. Our true living on beyond our short visit here on mortal earth does not live in a book, trophy or award but lives in what values we instill in our children. One word we may have shared with them may have made a difference. Those words I pray then echo into following generations. My desire here is to write a memoir touching on my... View Details
Multiple myeloma is the second most prevalent hematologic cancer after non-Hodgkin lymphoma. While great strides have been made to improve survival rates with this disease, and positive outcomes have been attained over the last ten years, multiple myeloma remains an incurable disease. The purpose of this course is to provide healthcare professionals in contact with multiple myeloma patients the information necessary to provide optimum care, treatment, and patient education. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter... View Details
NCCN Guidelines for Patients®: Multiple Myeloma, Version 1.2016
by National Comprehensive Cancer Network® (NCCN®) (Author)
[THIS BOOK IS OUT OF DATE] Please see the official current version. View Details